Anthelmintic Drugs Market Outlook Highlights The Next Major Growth Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Anthelmintic Drugs Market Forecast: What Market Value Is Expected By 2030?
The anthelmintic drugs market has experienced notable expansion over the past several years. Projections indicate that its value will increase from $3.34 billion in 2025 to $3.53 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.5%. This historical growth has been significantly driven by a high incidence of parasitic infections, restricted availability of newer anthelmintic treatments, continued dependence on conventional drug categories, heightened awareness regarding helminthic diseases, and a broadening network of hospital and clinic facilities.
The market for anthelmintic drugs is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $4.32 billion, reflecting a compound annual growth rate (CAGR) of 5.2%. This forecasted growth is driven by factors such as the creation of new anthelmintic compounds, a rising inclination toward combination therapies, heightened use in veterinary and livestock applications, the broadening of online and retail pharmacy networks, and governmental efforts to support parasite control initiatives. Key developments shaping this period include the growing frequency of helminth infections affecting both humans and animals, a shift toward oral anthelmintics and injectable formulations, increased requirements for veterinary anthelmintics in livestock farming, the wider availability of these drugs through retail and digital pharmacies, and an emphasis on combination therapies and broad-spectrum treatments.
Download A Free Sample Report For Comprehensive Market Insights:
Anthelmintic Drugs Market Development Factors: Which Trends Are Supporting Demand?
The growing frequency of parasitic infections is anticipated to boost expansion in the anthelmintic drugs market going forward. These infections are brought about by organisms such as protozoa, worms, or ectoparasites that live on or inside a host. Factors like poor sanitation, contaminated food or water, close contact with infected individuals or animals, inadequate hygiene, and limited access to clean resources contribute to their spread. Anthelmintic drugs work by targeting and removing parasitic worms from the host, often by interfering with their biological functions to cause expulsion or death. For example, in September 2025, data from the Centers for Disease Control and Prevention, a US public health agency, reported 990 cases of cyclosporiasis acquired in the United States as of that date. Consequently, the high prevalence of these infections is fueling growth in the anthelmintic drugs market.
Anthelmintic Drugs Market Segmentation: How Is The Market Structured Across Key Categories?
The anthelmintic drugs market covered in this report is segmented –
1) By Drug Class: Benzimidazoles, Macrocyclic lactones, Pyrazinoisoquinolones, Tetrahydropyrimidines, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Infection Type: Nematode Infections, Cestode Infections, Trematode Infections, Mixed Infections
4) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Online Pharmacies, Veterinary Clinics And Supply Stores
5) By Application: Human Anthelmintics, Veterinary Anthelmintics
Subsegments:
1) By Benzimidazoles: Albendazole, Mebendazole, Fenbendazole, Oxfendazole, Thiabendazole
2) By Macrocyclic Lactones: Ivermectin, Moxidectin, Doramectin, Eprinomectin, Milbemycin Oxime
3) By Pyrazinoisoquinolones: Praziquantel, Cysticide
4) By Tetrahydropyrimidines: Pyrantel Pamoate, Pyrantel Tartrate
5) By Other Drug Classes: Imidazothiazoles, Aminoacetonitrile Derivatives, Spiroindoles, Arsenicals
Anthelmintic Drugs Market Transformation Trends: Which Innovations Are Driving Change?
Leading players in the anthelmintic drugs market are prioritizing targeted, evidence-based deworming initiatives over traditional blanket approaches that involve frequent, indiscriminate treatments, aiming to enhance parasite control, curb drug resistance, and encourage more sustainable medication use. These strategic deworming programs incorporate diagnostic testing, parasite burden evaluation, and carefully timed dosing regimens to boost treatment effectiveness while lowering environmental and resistance concerns. For example, in April 2025, Zoetis Inc., an animal health firm headquartered in the US, introduced the “Buy Less Dewormer” campaign tailored to equine populations, advocating for parasite management grounded in scientific evidence. This initiative pairs educational resources with instructions for fecal egg count monitoring and thoughtful selection of anthelmintics; it works by motivating horse owners and veterinarians to administer treatments only when warranted, based on infection levels and risk assessments; its distinctive aspects involve integrated learning materials, risk-informed treatment suggestions, and backing for responsible anthelmintic stewardship; applications cover equine herd health management, countering resistance development, and fine-tuned deworming timetables; advantages encompass decreased overuse of anthelmintics, better parasite management results, reduced expenses for owners, and sustained drug potency over time.
Anthelmintic Drugs Market Competitive Landscape And Leading Companies
Major companies operating in the anthelmintic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Zoetis Inc., Hetero Labs Limited, Sun Pharmaceutical Industries Ltd., Galderma S.A., Cipla Inc., Ferring Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Mankind Pharma Ltd., Reese Pharmaceutical Company
Access The Complete Anthelmintic Drugs Market Report:
Anthelmintic Drugs Market Regional Analysis And Leading Geography
North America was the largest region in the anthelmintic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthelmintic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
